Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug Abilify AND Aripiprazole

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Drug Abilify AND Aripiprazole. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-000903-17 Sponsor Protocol Number: CN138-166 Start Date*: 2005-02-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Functioning of a Treatment with Aripiprazole in a Broad Range of Schizophrenic Patients
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003488-23 Sponsor Protocol Number: 31-12-293 Start Date*: 2013-01-30
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder
    Medical condition: Tics associated with Tourette’s Disorder in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) FI (Prematurely Ended) BE (Completed) SE (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed) DE (Prematurely Ended) NL (Not Authorised) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018858-12 Sponsor Protocol Number: 31-08-256 Start Date*: 2010-12-15
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder.
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed) SK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002676-10 Sponsor Protocol Number: 31-07-247 Start Date*: 2008-12-02
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) EE (Completed) HU (Completed) AT (Completed) FR (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004404-18 Sponsor Protocol Number: ARIANNA Start Date*: 2021-12-15
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: The impact of aripiprazole long-acting on myelin and cognition in the onset of schizophrenia
    Medical condition: Onset of schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003489-42 Sponsor Protocol Number: 31-12-294 Start Date*: 2013-03-12
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder
    Medical condition: Tics associated with Tourette’s Disorder in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) ES (Prematurely Ended) IT (Completed) DE (Ongoing) SE (Completed) NL (Ongoing) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012567-33 Sponsor Protocol Number: 331-07-203 Start Date*: 2009-11-18
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 2, 6-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Tr...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001064 Acute schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-022307-22 Sponsor Protocol Number: BergenPsychosisProject2 Start Date*: 2011-04-14
    Sponsor Name:Haukeland University Hospital, Division of Psychiatry
    Full Title: The Bergen Psychosis Project 2
    Medical condition: Patients with schizophrenia and related non-affective psychotic disorders, corresponding to ICD-10 diagnoses F10.5-19.5, and F20-29.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018911-13 Sponsor Protocol Number: 31-09-267 Start Date*: 2011-06-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients with Schizophrenia...
    Medical condition: Schizophrenia in Adolescent Patients or Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    14.1 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014811-11 Sponsor Protocol Number: R076477PSZ3003 Start Date*: 2010-01-25
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, controlado, de dosis flexibles y grupos paralelos para evaluar la eficacia y seguridad de paliperidona de liberación prolongada en el tratamiento d...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039626 Schizophrenia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) SK (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002765-30 Sponsor Protocol Number: ABR49490 Start Date*: 2015-06-12
    Sponsor Name:EGRIS
    Full Title: European Long-acting Antipsychotics in Schizofrenia Trial EULAST
    Medical condition: Schizophrenia ICD-10 code F20
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) AT (Completed) IT (Completed) NO (Completed) BE (Completed) ES (Completed) DK (Completed) HU (Completed) RO (Suspended by CA) CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001447-12 Sponsor Protocol Number: 331-10-234 Start Date*: 2019-01-11
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo- and Active controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 years old) With Schizophr...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10039636 Schizophrenia simple LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) PL (Completed) BG (Prematurely Ended) FR (Ongoing) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-001397-32 Sponsor Protocol Number: 2480/2008 Start Date*: 2008-05-14
    Sponsor Name:ASL 5 di PISA-ZONA VALDERA
    Full Title: ARIPIPRAZOLE VERSUS ROPIRINOLE: A PILOT , OPEN-LABEL, PROSPECTIVE, RANDOMISED, CONTROLLED, MULTICENTRIC TRIAL, IN THERAPY WITH ROPIRINOLE OR ARIPIPRAZOLE FOR COCAINE DEPENDENCE
    Medical condition: TERAPY FOR COCAINE DEPENDENCE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009815 Cocaine addiction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003850-26 Sponsor Protocol Number: 31-11-284 Start Date*: 2012-01-30
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with Aripiprazole IM Depot Compared with 6-month Retrospectiv...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005399-16 Sponsor Protocol Number: ROAC2014 Start Date*: 2014-08-05
    Sponsor Name:Dr. Benedicto Crespo. Servicio Psiquiatría. Hospital Universitario Marqués de Valdecilla/IDIVAL
    Full Title: Randomized, flexible-dose, open-label comparison to investigate the effectivenes of second generation antipsychotics in first episode psychosis patients.
    Medical condition: FIRST EPISODE DRUG-NAÏVE OF PSYCHOSIS (SCHIZOPHRENIA SPECTRUM DISORDERS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000456-29 Sponsor Protocol Number: FCD-ADA-1401 Start Date*: 2014-10-31
    Sponsor Name:Ferrer Internacional, S.A.
    Full Title: EFFICACY AND SAFETY OF INHALED LOXAPINE COMPARED WITH IM ANTIPSYCHOTIC IN ACUTELY AGITATED PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
    Medical condition: SCHIZOPHRENIA AND BIPOLAR DISORDER
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    19.0 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017024-82 Sponsor Protocol Number: HSJD-EPEP09 Start Date*: 2012-01-02
    Sponsor Name:FUNDACIÓN SANT JOAN DE DEU
    Full Title: Clinical and neuropsychological factors associated with second generation antipsychotic response in patients diagnosed with first episode of early onset schizophrenia spectrum disorders
    Medical condition: First episode of early onset schizophrenia spectrum disorders
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10040705 Simple schizophrenia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003434-24 Sponsor Protocol Number: ACP-103-034 Start Date*: 2017-04-28
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) CZ (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003436-20 Sponsor Protocol Number: ACP-103-038 Start Date*: 2017-04-28
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) ES (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003435-38 Sponsor Protocol Number: ACP-103-035 Start Date*: 2017-04-28
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Ongoing) BG (Prematurely Ended) CZ (Completed) DE (Prematurely Ended) LT (Completed) PL (Prematurely Ended) IT (Prematurely Ended) HR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:34:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA